KR102245702B1 - 셀렌을 포함하는 조성물 및 미토콘드리아 기능장해와 관련된 질병 또는 상태의 치료와 예방을 위한 이의 용도 - Google Patents

셀렌을 포함하는 조성물 및 미토콘드리아 기능장해와 관련된 질병 또는 상태의 치료와 예방을 위한 이의 용도 Download PDF

Info

Publication number
KR102245702B1
KR102245702B1 KR1020157029100A KR20157029100A KR102245702B1 KR 102245702 B1 KR102245702 B1 KR 102245702B1 KR 1020157029100 A KR1020157029100 A KR 1020157029100A KR 20157029100 A KR20157029100 A KR 20157029100A KR 102245702 B1 KR102245702 B1 KR 102245702B1
Authority
KR
South Korea
Prior art keywords
selenium
subject
composition
yeast
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157029100A
Other languages
English (en)
Korean (ko)
Other versions
KR20150132374A (ko
Inventor
로난 파워
캐시 이건
알렉산더 야니코우리스
지 지안 란
리진 시아오
루이스 콜렌 젝슨
스테판 퀴아트코우스키
Original Assignee
올텍 법인회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 올텍 법인회사 filed Critical 올텍 법인회사
Publication of KR20150132374A publication Critical patent/KR20150132374A/ko
Application granted granted Critical
Publication of KR102245702B1 publication Critical patent/KR102245702B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020157029100A 2013-03-15 2014-03-14 셀렌을 포함하는 조성물 및 미토콘드리아 기능장해와 관련된 질병 또는 상태의 치료와 예방을 위한 이의 용도 Active KR102245702B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361788133P 2013-03-15 2013-03-15
US61/788,133 2013-03-15
PCT/US2014/029328 WO2014144776A1 (en) 2013-03-15 2014-03-14 Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction

Publications (2)

Publication Number Publication Date
KR20150132374A KR20150132374A (ko) 2015-11-25
KR102245702B1 true KR102245702B1 (ko) 2021-04-28

Family

ID=51537786

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157029100A Active KR102245702B1 (ko) 2013-03-15 2014-03-14 셀렌을 포함하는 조성물 및 미토콘드리아 기능장해와 관련된 질병 또는 상태의 치료와 예방을 위한 이의 용도

Country Status (15)

Country Link
US (1) US9833486B2 (enExample)
EP (1) EP2968404B1 (enExample)
JP (1) JP6313418B2 (enExample)
KR (1) KR102245702B1 (enExample)
CN (3) CN105377271A (enExample)
AU (1) AU2014228785B2 (enExample)
BR (1) BR112015022514A2 (enExample)
CA (1) CA2903845C (enExample)
CL (1) CL2015002677A1 (enExample)
HK (1) HK1216506A1 (enExample)
MX (1) MX359626B (enExample)
RU (1) RU2663127C2 (enExample)
SG (2) SG10202101918RA (enExample)
WO (1) WO2014144776A1 (enExample)
ZA (1) ZA201506759B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016513712A (ja) 2013-03-14 2016-05-16 ジェローム， ジェイ． シェンターク， カイロミクロンへの分子の取り込みのためのコレストソーム小胞
MX2016011897A (es) * 2014-03-14 2017-04-27 Alltech Inc Composiciones de compuestos selenoorganicos y metodos de uso de los mismos.
US10639322B2 (en) 2015-03-27 2020-05-05 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
WO2017048252A1 (en) * 2015-09-15 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
AU2017234662A1 (en) * 2016-03-14 2018-10-04 Mitogenetics, Llc Materials and methods for treating hypoxic conditions
CN120647702A (zh) 2017-05-19 2025-09-16 全技术公司 药剂、组合物及其相关方法
CA3090241C (en) * 2018-04-25 2023-03-28 Oncocross Co.,Ltd. Composition for preventing and treating muscular disease
CN108283711A (zh) * 2018-05-06 2018-07-17 冷立娟 一种治疗酒精性心肌病的中药冲剂及其制备方法
CN109820933A (zh) * 2019-02-27 2019-05-31 北京曲佳科技有限公司 减肥片及其制备方法
CN111493325A (zh) * 2020-05-07 2020-08-07 恩施德源健康科技发展有限公司 植物硒肽在制备改善肥胖及代谢综合征组合物中的应用
CN115917310A (zh) * 2020-06-29 2023-04-04 百时美施贵宝公司 用于分析来自生物反应器的样品的自动化系统和方法
CN112129864B (zh) * 2020-09-24 2022-04-01 江南大学 一种富硒植物干粉中硒形态测定的方法
KR102328808B1 (ko) * 2020-12-02 2021-11-22 동의대학교 산학협력단 맥주효모를 이용한 근감소증 예방 및 개선용 조성물
CN114053298A (zh) * 2021-11-19 2022-02-18 华中农业大学 一种用于抑制心肌肥大的药物及模型的构建方法
CN114235989A (zh) * 2021-11-27 2022-03-25 山东省烟台市农业科学研究院 一种测定福美甲胂含量的高效液相色谱法
CN114031650B (zh) * 2021-11-29 2023-05-02 上海交通大学 壳寡糖硒配位化合物及其制备方法和应用
CN114924001B (zh) * 2022-05-12 2024-11-19 中国计量科学研究院 一种基于独立校准的含磷或含硒化合物标准溶液定值方法
CN114931569B (zh) * 2022-06-22 2023-05-16 中国农业科学院油料作物研究所 甲基硒代半胱氨酸在制备提高雄性生殖能力的产品中的应用
CN116333302B (zh) * 2023-03-31 2024-09-10 中南大学 一种稳定持久抗氧化纳米点及其在二型糖尿病中的应用
CN116421618B (zh) * 2023-06-15 2023-09-29 暨南大学 Se@NADH的制备方法及其在脊髓损伤治疗中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080286382A1 (en) * 2007-05-18 2008-11-20 Alltech, Inc. Compositions and methods for establishing and/or maintaining pregnancy

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5896024A (ja) * 1981-10-16 1983-06-07 リチヤ−ド・エフ・ストツケル 白金毒解毒剤
US5221545A (en) 1992-03-09 1993-06-22 Abbott Laboratories Method of providing selenium in a nutritional product
US6197295B1 (en) 1996-09-25 2001-03-06 Viva America Marketing Corporation Dietary supplementation with, and methods for administration of yeast-derived selenium product
US6911550B2 (en) 2003-02-21 2005-06-28 Zinpro Corporation Derivatives of seleno-amino acids with improved bioavailability and method for their preparation
WO2004107881A1 (en) * 2003-06-04 2004-12-16 Serfontein, Willem, Jacob Nutritional compositions and use thereof
PL214402B1 (pl) * 2003-08-11 2013-07-31 Tomasz Byrski Zastosowanie selenu albo jego zwiazku do otrzymywania srodka do obnizania odziedziczonego ryzyka zachorowania na raka piersi lub jajnika
US20050069594A1 (en) 2003-08-11 2005-03-31 Jan Lubinski Pharmaceutical compositions and methods for the prevention of breast and ovarian cancer
WO2005023274A1 (en) * 2003-09-05 2005-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
US8871715B2 (en) * 2005-10-14 2014-10-28 Alltech, Inc. Use of selenium compounds, especially selenium yeasts for altering cognitive function
AU2005227420B2 (en) * 2005-10-14 2013-05-09 Alltech, Inc. Method and compositions for altering cell function
US20100247679A1 (en) * 2006-04-24 2010-09-30 Alltech, Inc. Methods and compositions for altering cell function
CA2694928A1 (en) * 2007-07-31 2009-02-05 Board Of Regents, The University Of Texas System Micro-rnas that control myosin expression and myofiber identity
EP2192905A4 (en) * 2007-08-29 2010-11-10 Adam Lubin METHOD FOR SELECTIVE THERAPY OF DISEASE
BRPI0818007A2 (pt) * 2007-10-16 2015-11-03 Exichol Sa composição para regular o metabolismo lipídico
CN101579355B (zh) * 2009-05-27 2010-12-08 徐建兴 一种维护线粒体功能的营养组合物及其应用
SG10201406651PA (en) * 2009-10-22 2014-11-27 Propanc Pty Ltd A pharmaceutical composition for treating cancer comprising trypsinogen and/orchymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compoundand a cytoplasmic glycolysis reduction agent
US8575320B2 (en) 2010-03-18 2013-11-05 Alltech, Inc. Compositions and methods for separating, characterizing and administering soluble selenoglycoproteins
US8883498B2 (en) * 2010-04-22 2014-11-11 Kyoto University Method for inducing differentiation of pluripotent stem cells into skeletal muscle or skeletal muscle progenitor cells
KR20120048205A (ko) * 2010-11-05 2012-05-15 한국식품연구원 메틸셀레노시스테인을 유효성분으로 함유하는 비만 및 지질 관련 대사성 질환의 예방 및 치료용 조성물
WO2012141316A1 (ja) * 2011-04-13 2012-10-18 味の素株式会社 栄養組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080286382A1 (en) * 2007-05-18 2008-11-20 Alltech, Inc. Compositions and methods for establishing and/or maintaining pregnancy

Also Published As

Publication number Publication date
US9833486B2 (en) 2017-12-05
CN105377271A (zh) 2016-03-02
CL2015002677A1 (es) 2016-12-09
CN114984038A (zh) 2022-09-02
BR112015022514A2 (pt) 2017-07-18
SG11201507061XA (en) 2015-10-29
WO2014144776A1 (en) 2014-09-18
AU2014228785B2 (en) 2018-01-25
NZ711842A (en) 2021-04-30
MX2015013275A (es) 2015-12-11
JP2016516058A (ja) 2016-06-02
CN114533753A (zh) 2022-05-27
JP6313418B2 (ja) 2018-04-18
EP2968404A1 (en) 2016-01-20
RU2015139742A (ru) 2017-04-21
MX359626B (es) 2018-10-01
RU2663127C2 (ru) 2018-08-01
SG10202101918RA (en) 2021-03-30
KR20150132374A (ko) 2015-11-25
CA2903845C (en) 2022-08-23
EP2968404B1 (en) 2026-07-22
HK1216506A1 (zh) 2016-11-18
CA2903845A1 (en) 2014-09-18
AU2014228785A1 (en) 2015-09-24
ZA201506759B (en) 2017-03-29
EP2968404A4 (en) 2017-01-04
US20160113977A1 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
US9833486B2 (en) Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
Liu et al. The physiological metabolite α-ketoglutarate ameliorates osteoarthritis by regulating mitophagy and oxidative stress
Yuan et al. Exercise‐induced α‐ketoglutaric acid stimulates muscle hypertrophy and fat loss through OXGR1‐dependent adrenal activation
He et al. Serine is required for the maintenance of redox balance and proliferation in the intestine under oxidative stress
Ru et al. Iron homeostasis and ferroptosis in muscle diseases and disorders: mechanisms and therapeutic prospects
Bakar et al. Celastrol attenuates inflammatory responses in adipose tissues and improves skeletal muscle mitochondrial functions in high fat diet-induced obese rats via upregulation of AMPK/SIRT1 signaling pathways
JP6313479B2 (ja) 有機セレン化合物の組成物およびその使用方法
López‐Hernández et al. The endoplasmic reticulum stress and the HIF‐1 signalling pathways are involved in the neuronal damage caused by chemical hypoxia
Wang et al. Nitration-mediated deficiency of cystathionine β-synthase activity accelerates the progression of hyperhomocysteinemia
EP2434010A1 (en) Prophylactic and/or therapeutic agent for metabolic syndrome
Xu et al. Longevity-promoting properties of ginger extract in Caenorhabditis elegans via the insulin/IGF-1 signaling pathway
De Riccardis et al. Metabolic response to glatiramer acetate therapy in multiple sclerosis patients
He et al. Collagen peptides alleviate hyperglycemia in mice by modulating insulin resistance, glucose metabolism and gut microbiota
Ren et al. Astaxanthin slows down skeletal muscle atrophy in H22 tumor-bearing mice during sorafenib treatment by modulating the gut microbiota
CN111888359A (zh) 一种吡咯喹啉醌在抗哮喘及变态反应药物中的应用
Wang et al. Integrated proteomics and metabolomics to clarify the essential beneficial mechanisms of L-theanine in alleviating ISO-induced cardiac damage in mice
Kang et al. Inhibition of MAT2A suppresses osteoclastogenesis and prevents ovariectomy‐induced bone loss
US10314814B2 (en) Composition comprising 7-hydroxymatairesinol
JP7843342B2 (ja) ｅＮＡＭＰＴ増加剤、サーチュイン活性化又は発現増強剤、ＮＡＤ＋増加剤、及び老化細胞抑制剤
Luo et al. The effect of RDP on cell proliferation and apoptosis of porcine Leydig cells with hypoxia
NZ711842B2 (en) Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
He et al. Testosterone-promoting effects of Trichosanthes kirilowii-derived peptides on TM3 cells
Ahn et al. Unacylated Ghrelin Counteracts Contractile and Mitochondrial Dysfunction in Cancer Cachexia
Yang et al. Comprehensive analysis of yak milk residue peptides for anti-hypoxic functional foods: targeting neuroinflammation and apoptosis in hypoxic mice
Li et al. The cinnamaldehyde-thiosemicarbazone-zinc (II) complex induces apoptosis in CAL-27 cells

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151013

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190312

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200728

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210125

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210422

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210422

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20250403

Start annual number: 5

End annual number: 5